JESSICA GANDHI: Open Payments
NPI 1003226036 · CHEVY CHASE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$11,847 in 136 payments from 25 companies in 2025. Trend: 2023 $880 · 2024 $2,096 · 2025 $11,847
Consulting: $6,210Food & beverage: $4,565Travel & lodging: $521Speaker / faculty: $500Education: $51
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 28 | $8,286 |
| Ardelyx, Inc. | 22 | $857 |
| Janssen Biotech, Inc. | 13 | $679 |
| ABBVIE INC. | 13 | $386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $284 |
| GENZYME CORPORATION | 6 | $255 |
| QOL Medical, LLC | 7 | $182 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Lilly USA, LLC | 4 | $94 |
| Phathom Pharmaceuticals, Inc. | 5 | $89 |
Products named: REZDIFFRA, IBSRELA, TREMFYA, DUPIXENT, ENTYVIO, Sucraid, RINVOQ, SKYRIZI.
Industry payments across MD — which companies pay providers there.
